endeavor ii
DESCRIPTION
ENDEAVOR II. Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively Death: 1.2% vs. 0.5% (p = 0.34), respectively Stent thrombosis: 0.5% vs. 1.2%, respectively. - PowerPoint PPT PresentationTRANSCRIPT
ENDEAVOR II
• Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver
• Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively
• Death: 1.2% vs. 0.5% (p = 0.34), respectively
• Stent thrombosis: 0.5% vs. 1.2%, respectively
Trial design: Stable patients with native coronary disease were randomized to DES (n = 598) versus BMS (n = 599). Primary outcome was target vessel failure at 9 months.
Results
Conclusions
• Among stable patients undergoing PCI for a single de novo lesion, the use of the Endeavor drug-eluting stent was beneficial.
• This stent reduced target vessel failure and target lesion revascularization compared with a Driver bare-metal stent.
Fajadet J, et al. Circulation 2006;114:798-806
(p = 0.0001)
(p = 0.22)
DES BMS
%
Target vessel failure Stent thrombosis
7.9
15.1
0.5 1.2